• Inspire Medical Systems, Inc. (NYSE:INSP) receives a "Buy" rating from Stifel Nicolaus with a price target of $110, indicating a potential increase of 22.4%.
• The company is currently facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934.
• Despite legal challenges, INSP's stock price shows an increase, with a current price of $89.87 and a trading volume of 1,073,158 shares on the NYSE.

Inspire Medical Systems, Inc. (NYSE:INSP) is a company that specializes in innovative medical solutions, particularly focusing on sleep apnea treatments. The company is known for its Inspire therapy, an implantable device that helps patients with obstructive sleep apnea. As of November 24, 2025, Jonathan Block from Stifel Nicolaus set a price target of $110 for INSP, suggesting a potential increase of 22.4% from its current price of $89.87. This upgrade to a "Buy" rating was highlighted by StreetInsider.

Despite the positive outlook from Stifel Nicolaus, Inspire Medical Systems is currently dealing with a class action lawsuit. The Schall Law Firm, a national shareholder rights litigation firm, is leading the lawsuit, alleging violations of the Securities Exchange Act of 1934. This legal action involves investors who purchased INSP securities between August 6, 2024, and August 4, 2025. Shareholders who have experienced losses are encouraged to contact the firm before January 5, 2026.

The stock price of INSP is currently $89.87, showing an increase of 7.92% or $6.60. Today, the stock has fluctuated between $83.37 and $90.55. Over the past year, INSP has seen a high of $216.01 and a low of $70.77. The company's market capitalization stands at approximately $2.66 billion, indicating its size and presence in the market.

The trading volume for INSP on the NYSE is 1,073,158 shares, reflecting active investor interest. Despite the ongoing legal challenges, the stock's recent performance and the positive analyst outlook suggest potential growth. Investors should consider both the legal proceedings and the analyst's price target when evaluating INSP's future prospects.